Ignite Creation Date:
2024-05-06 @ 6:35 PM
Last Modification Date:
2024-10-26 @ 2:50 PM
Study NCT ID:
NCT05712902
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-02-06
First Post:
2023-01-12
Brief Title:
DZD9008 in Pretreated Lung Cancer Patients With EGFR Exon20 Insertion Mutation
Sponsor:
Dizal Pharmaceuticals
Organization:
Dizal Pharmaceuticals
Study Overview
Official Title:
A Phase II Single Arm Multicenter Study to Evaluate Anti-tumor Activity Safety Tolerability and Pharmacokinetics of DZD9008 in Locally Advanced or Metastatic Non-Small Cell Lung Cancer NSCLC With EGFR Exon 20 Insertion Mutation
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase II single-arm multi-center clinical study to evaluate the anti-tumor efficacy safety tolerability and pharmacokinetics of DZD9008 in participants with locally advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations whose disease has progressed on prior platinum-based chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None